Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed in Recurrent Platinum-Resistant Ovarian or Primary Peritoneal Carcinoma
NCT00087087Phase 2Completed
- Sponsor
- GOG Foundation
- Start
- Jul 2004
- Primary completion
- Dec 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed in ovarian epithelial cancer and primary peritoneal cancer (PPC), sponsored by GOG Foundation. Primary endpoints: Antitumor activity and Toxicity. Started Jul 2004; status: completed.
02
Drugs
pemetrexed
03
Conditions
ovarian epithelial cancerprimary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00087087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00087087.